tetano
Editor, Senior Moderator
J Virol Methods
. 2020 Nov 2;287:114009.
doi: 10.1016/j.jviromet.2020.114009. Online ahead of print.
A High-throughput Anti-SARS-CoV-2 IgG Testing Platform for COVID-19
Jinwei Du[SUP] 1 [/SUP], Eric Chu[SUP] 1 [/SUP], Dayu Zhang[SUP] 1 [/SUP], Chuanyi M Lu[SUP] 2 [/SUP], Aiguo Zhang[SUP] 1 [/SUP], Michael Y Sha[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection.
Objective: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection.
Results: Clinical agreement studies were performed in 107 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15% (95% CI: 19.22% ∼74.87%), 61.54% (95% CI: 31.58% ∼86.14%), and 97.53% (95% CI: 91.36% ∼99.70%) for samples collected on 0-7 days, 8-14 days, and ≥15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23% (95% CI: 95.53% ∼99.52%). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay.
Conclusion: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up anti-SARS-CoV-2 IgG testing.
Keywords: COVID-19; IgG Test; Immunoassay; SARS-CoV-2.
. 2020 Nov 2;287:114009.
doi: 10.1016/j.jviromet.2020.114009. Online ahead of print.
A High-throughput Anti-SARS-CoV-2 IgG Testing Platform for COVID-19
Jinwei Du[SUP] 1 [/SUP], Eric Chu[SUP] 1 [/SUP], Dayu Zhang[SUP] 1 [/SUP], Chuanyi M Lu[SUP] 2 [/SUP], Aiguo Zhang[SUP] 1 [/SUP], Michael Y Sha[SUP] 3 [/SUP]
Affiliations
- PMID: 33152411
- PMCID: PMC7605757
- DOI: 10.1016/j.jviromet.2020.114009
Abstract
Background: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection.
Objective: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection.
Results: Clinical agreement studies were performed in 107 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15% (95% CI: 19.22% ∼74.87%), 61.54% (95% CI: 31.58% ∼86.14%), and 97.53% (95% CI: 91.36% ∼99.70%) for samples collected on 0-7 days, 8-14 days, and ≥15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23% (95% CI: 95.53% ∼99.52%). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay.
Conclusion: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up anti-SARS-CoV-2 IgG testing.
Keywords: COVID-19; IgG Test; Immunoassay; SARS-CoV-2.